About In Silico Toxicology & Safety Prediction
In Silico Toxicology & Safety Prediction covers the software toxicologists, medicinal chemists, and regulatory scientists use to assess hazard liabilities from chemical structure before — or instead of — running wet assays. The category exists because programs need to triage thousands of candidate molecules, qualify genotoxic impurities under ICH M7, and defend safety conclusions to regulators using reproducible, documented predictions. That creates a persistent tension: models must be transparent enough for submission dossiers, broad enough to cover endpoints from Ames mutagenicity to organ-level toxicity, and fast enough to sit inside discovery workflows where structures change daily.
The composition of this subdomain reflects those constraints. Around three quarters of tools are AI/ML-driven, and computational engines dominate over standalone databases or analytical front-ends, suggesting buyers are integrating predictions into existing pipelines rather than adopting all-in-one environments. Deployment splits almost evenly between cloud and on-premise, an unusual pattern that points to ongoing sensitivity around proprietary structures leaving the firewall. ICH alignment appears in roughly 60% of listings, while GxP and ISO 27001 coverage remains rare — a signal that most offerings target scientific assessment workflows rather than validated regulated systems.
Browse Predictive Tox Software
Predict Abraham solvation parameters and partition coefficients directly from chemical structure.
Structure-based prediction of absorption, distribution, metabolism, and excretion properties for drug discovery and high-throughput screening.
ADMET Predictor by Simulations Plus
AI/ML prediction of 175+ ADMET and pharmacokinetic properties, including metabolism, toxicity, and solubility, with integrated PBPK simulation and AI-driven drug design.
Weight of Evidence assessment for carcinogenicity risk using six integrated modules aligned with ICH S1B guidelines.
AI-powered ADMET prediction across 13 endpoints including solubility, permeability, stability, and toxicity.
Bio-AI Clinical Prediction Platform by Quris AI
Drug safety prediction using machine learning trained on patients-on-a-chip data.
Early toxicology risk assessment and safety prediction for drug development using integrated preclinical and clinical data.
Cytocast Digital Twin Platform by Cytocast
Protein complex simulation and AI-powered off-target and side effect prediction for drug safety assessment.
Cytocast Screener, Cytocast Optimizer, and Cytocast Nominator by Cytocast
AI-powered drug side-effect prediction using Digital Twin technology for early candidate prioritization.
Common Questions About In Silico Toxicology & Safety Prediction
What is In Silico Toxicology & Safety Prediction software?
These are computational tools that predict toxicological endpoints — mutagenicity, carcinogenicity, hepatotoxicity, metabolic fate, impurity risk — from chemical structure, using structural alerts, QSAR models, expert rule systems, and curated toxicity databases. Toxicologists, medicinal chemists, and regulatory affairs teams use them to triage candidates early, qualify impurities under ICH M7, and assemble weight-of-evidence assessments without generating new animal or in vitro data for every query.
What should I evaluate when choosing a platform in this category?
Key axes include endpoint coverage and the provenance of the underlying training data, the balance between statistical models and expert rule systems, transparency of predictions for regulatory defensibility, applicability domain reporting, and the format of output documentation. Integration with existing chemistry registration systems and the ability to handle batch impurity workflows matter for production use. Deployment model is also significant given that on-premise and cloud options are roughly evenly represented.
How do these tools fit ICH M7 and other regulatory expectations?
ICH M7 explicitly accepts (Q)SAR predictions for mutagenicity assessment of impurities when two complementary methodologies — typically one statistical and one expert rule-based — are applied. Around 60% of tools in the category document ICH alignment. Buyers should confirm that prediction reports include applicability domain, supporting evidence, and expert review fields suitable for submission dossiers. GxP and ISO 27001 coverage is much thinner and concentrated in vendor-hosted offerings.
How does this differ from PBPK or systems pharmacology modeling within the parent category?
PBPK and quantitative systems pharmacology tools simulate exposure, distribution, and dynamic biological response over time, typically requiring physicochemical and ADME parameters as inputs. In silico toxicology works upstream from structure alone, flagging hazard liabilities before dosing assumptions exist. The two are complementary: structure-based hazard screening narrows candidates, and PBPK then contextualizes exposure margins for the survivors. Many programs use both at different decision gates.
Are open-source options viable for regulatory submissions here?
The directory currently lists no open-source entries in this subdomain, which reflects the reality that regulators expect validated, versioned models with documented training sets and locked prediction logic. Open frameworks exist in the broader cheminformatics ecosystem, but submission-grade workflows typically rely on commercial knowledge bases and curated databases where model provenance, update cycles, and reproducibility of predictions are contractually maintained.
Other subdomains within Computational Drug Safety & PKPD Modeling
Clinical Trial Simulation & Forecasting
Tools that use AI and computational modeling to simulate clinical trials, predict trial outcomes and probability of success, generate synthetic patient populations, and optimize trial protocols and portfolio decisions before or during drug development.
Physiologically-Based PK Modeling (PBPK) & Systems Pharmacology
Software platforms that use mechanistic, physiologically-based, or quantitative systems pharmacology and toxicology models to simulate drug absorption, pharmacokinetics, organ-level safety, and treatment efficacy across diverse populations and disease states.
Companies with the largest Predictive Tox software portfolios
Lhasa
- In silico software and precompetitive data sharing for chemical safety assessment in pharmaceuticals, cosmetics, and chemistry.
ACD/Labs
- Analytical chemistry informatics, chemical nomenclature, and in silico predictions for R&D laboratories.
Instem
- Data management, predictive analytics, study management, and regulatory submission for drug discovery and clinical research.